Clinical Trial Update: A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 1]

View source ↗

Summary

A Phase Ib, multicenter, open-label study to evaluate multiple-dose EA5 in adults with paroxysmal nocturnal hemoglobinuria is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• EA5

Snippet

Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. | Conditions: PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Status: RECRUITING